GCTransplant

Advancing clinical innovation to positively impact long-term outcomes for Canadian transplant recipients

Transplantation is the optimal treatment for patients with kidney failure, but rejection causes premature graft loss in as many as 30 percent of recipients. The Genome Canada Transplant Consortium (GCTC) brings together over 22 major universities, 70+ researchers, clinical programs, provincial transplant organizations, and commercial/industry partners in Canada, with significant international collaborations. The Precision Medicine in Transplantation Cluster draws together the leading researchers from GCTC and from various UBC departments to advance expertise in laboratory, clinical and therapeutic aspects of both solid organ and stem cell transplantation.

The core goal is to develop and implement novel genomic approaches for donor-patient matching, immune monitoring, and the personalization of immunosuppression, striving for operational tolerance & durable transplant outcomes.